Insight Molecular Diagnostics Inc. (IMDX) Institutional Ownership

Ownership Summary

Recent 13F filings as of September 2025 show that 26 institutional investors hold a position in Insight Molecular Diagnostics Inc. (NASDAQ:IMDX).

• The percentage of Insight Molecular Diagnostics owned by institutions changed from 53.3% in June 2025 to 56.7% in September 2025, marking a slight up trend.
• Quarterly data indicates a 6.67% shift in institutional share volume, and the annual owner count reflects an increase of 30.00%.
• The latest 13F cycle for Insight Molecular Diagnostics reveals that of 26 total investors, 8 funds grew their exposure, whereas 7 reduced theirs and 11 made no changes.
• This class of investors increased its holdings in Insight Molecular Diagnostics to 16.23Mn shares for the 13F-cycle ending September 2025, up by 1.02Mn shares quarter on quarter, and up 9.06Mn shares year over year.
• The top institutional stake in Insight Molecular Diagnostics as of September 30, 2025 belongs to BROADWOOD CAPITAL INC, which owns 11.41Mn shares, or 39.87% of the company.
• Among the most significant buyers of Insight Molecular Diagnostics during September 2025 were PURA VIDA INVESTMENTS, LLC (928.43K), MILLENNIUM MANAGEMENT LLC (55.78K), GEODE CAPITAL MANAGEMENT, LLC (40.87K), STATE STREET CORP (22.30K), Private Advisor Group, LLC (10.42K).
• Leading sellers of Insight Molecular Diagnostics stock in September 2025 included CITADEL ADVISORS LLC (37.00K), UBS Group AG (12.65K), Tower Research Capital LLC (TRC) (3.84K), RENAISSANCE TECHNOLOGIES LLC (2.50K), ORG Partners LLC (650).
• The top 10 institutional holders of Insight Molecular Diagnostics for the quarter ending September 2025 included BROADWOOD CAPITAL INC (11.41Mn), AWM Investment Company, Inc. (2.82Mn), PURA VIDA INVESTMENTS, LLC (947.13K), VANGUARD GROUP INC (486.74K), GEODE CAPITAL MANAGEMENT, LLC (198.45K), BlackRock, Inc. (87.95K), MILLENNIUM MANAGEMENT LLC (73.29K), MORGAN STANLEY (62.21K), STATE STREET CORP (41.85K), NORTHERN TRUST CORP (32.89K).